Chabiotech차바이오텍

Chabiotech's revenue is growing, but it still posts operating losses and its shares are down sharply over the past year.

Chabiotech, a KOSDAQ-listed biotech and healthcare group, reported trailing twelve-month revenue of ₩1.3T to H1 2026, with medical services as its largest revenue source. It remains loss-making at the operating level, with a trailing operating loss of ₩74B, though it posted a small trailing net profit of ₩14B. The share price closed at ₩7,030 on 2026-10-27, near its 52-week low of ₩7,000 and far below its 52-week high of ₩23,950.

What stands out

• Revenue rose 21.4% in 2025 to ₩1.27T, but operating income was still negative at -₩49B, and net income was -₩110B for the year.
• Trailing operating margin is -5.7% and free cash flow is -₩283B, so cash generation is weak despite ₩303B of reported cash.
• Borrowings of ₩161B and a liabilities-to-equity ratio of 178.4% indicate a heavily leveraged balance sheet.
• The trailing net profit of ₩14B is not matched by operating results, so the gap is not explained in the data provided.
• Foreign ownership fell from 8.5% to 7.3% over the past 60 days, and 20-day flows show foreign net selling of about ₩1.4B.

What to watch

• Filings on third-party collateral provisions appear repeatedly in September and October 2026, and amended versions were filed; the underlying terms are not in the data.
• Convertible preferred share and warrant price adjustments in September 2026 could affect dilution; the data does not give details.
• Upcoming results and the next half-year or annual filing will show whether operating losses are narrowing.